Biswa Mohan Sahoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Biswa Mohan Sahoo has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Bera Venkata Varaha Ravi Kumar
Department of Pharmaceutical Chemistry, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
12 shared publications - Bimal Krishna Banik
Department of Mathematics and Natural Sciences, College of Sciences and Human Studies, Prince Mohammad Bin Fahd University, Al Khobar, Kingdom of Saudi Arabia
11 shared publications - Abhishek Tiwari
IFTM University
9 shared publications - Krishna Chandra Panda
Department of Pharmaceutical Chemistry, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
9 shared publications - Shikha Sharma
Department of Pharmaceutical Sciences, Lords University, Alwar, Rajasthan, 301028, India
8 shared publications - Ashirbad Nanda
School of Pharmacy and Life Sciences, Centurion University of Technology & Management,Bhubaneswar, Khurda, 752050, Odisha, India
5 shared publications
Latest Publications
- 12 November 2026
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 17, 1-13
Nanoparticles in Targeted Cancer Therapy: Current Platforms, Resistance-Modulating Mechanisms, Clinical Translation, and Future Challenges
Cancer is one of the leading causes of death and morbidity, with a complicated pathophysiology. There are several conventional cancer therapies, including chemotherapy, radiation therapy, and immunotherapy. However, there are major challenges to effective cancer treatment, including cytotoxicity, lack of selectivity, and multidrug resistance. Nanoparticle-based drug delivery methods have emerged as an effective method to circumvent these constraints by facilitating targeted and precisely controlled drug delivery. Considering all of these facts, there has been a huge increase in demand in recent years for the development of innovative approaches for effective cancer treatment. Nanoparticles not only solve the limitations of conventional cancer therapy but also overcome multidrug resistance. The literature review illustrates that nanoparticles may accumulate in tumour tissues through the Enhanced Permeability and Retention (EPR) effect caused by abnormal tumor vasculature and impaired lymphatic drainage. Still, the degree of EPR-mediated accumulation varies significantly among patients and tumor types, and it may be less predictable in clinical circumstances than pre-clinical research implies. Ligand-mediated active targeting can enhance cellular uptake, whereas nanoparticle-based drug delivery methods may improve drug bioavailability, minimize systemic toxicity, and also help in overcoming multidrug resistance. In spite of these improvements, challenges related to stability, scalability, clinical translation, and regulatory approval remain substantial. Future advances in nanoparticle design and precision nanomedicine are expected to accelerate the development of safer, more efficient, and clinically feasible targeted cancer therapy.
- 12 November 2026
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 17, 1-13
Nanoparticles in Targeted Cancer Therapy: Current Platforms, Resistance-Modulating Mechanisms, Clinical Translation, and Future Challenges
Cancer is one of the leading causes of death and morbidity, with a complicated pathophysiology. There are several conventional cancer therapies, including chemotherapy, radiation therapy, and immunotherapy. However, there are major challenges to effective cancer treatment, including cytotoxicity, lack of selectivity, and multidrug resistance. Nanoparticle-based drug delivery methods have emerged as an effective method to circumvent these constraints by facilitating targeted and precisely controlled drug delivery. Considering all of these facts, there has been a huge increase in demand in recent years for the development of innovative approaches for effective cancer treatment. Nanoparticles not only solve the limitations of conventional cancer therapy but also overcome multidrug resistance. The literature review illustrates that nanoparticles may accumulate in tumour tissues through the Enhanced Permeability and Retention (EPR) effect caused by abnormal tumor vasculature and impaired lymphatic drainage. Still, the degree of EPR-mediated accumulation varies significantly among patients and tumor types, and it may be less predictable in clinical circumstances than pre-clinical research implies. Ligand-mediated active targeting can enhance cellular uptake, whereas nanoparticle-based drug delivery methods may improve drug bioavailability, minimize systemic toxicity, and also help in overcoming multidrug resistance. In spite of these improvements, challenges related to stability, scalability, clinical translation, and regulatory approval remain substantial. Future advances in nanoparticle design and precision nanomedicine are expected to accelerate the development of safer, more efficient, and clinically feasible targeted cancer therapy.
- 13 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 17, 1-17
Integrated Network Pharmacology, In Silico Analysis, and Experimental Validation to Reveal Antidiarrheal Activity of Psidium guajava L. Leaf Extract
Introduction: Psidium guajava L. (guava) is a well-known equatorial plant exploited for food and medicinal purposes. The present study is based on the antidiarrheal activity of the hydroalcoholic extract of its leaves in castor oil-induced diarrhea. Methods: The extract was analysed by GC-MS, and secondary metabolites were identified. The pharmacokinetic analysis and toxicity profiling of the identified components were performed. The network pharmacological analysis was performed to find compound-key target interaction pathways. In silico docking analysis was performed against epidermal growth factor receptor (EGFR) and prostaglandin E receptor 3 (EP3), and ligand binding efficiency was calculated. The diarrheal model was developed by administering castor oil and evaluated antidiarrheal activities using loperamide as a standard drug. Results: GC-MS identified major compounds that were screened for physicochemical properties and toxicity profiling, and network pharmacological pathways were established. GC-MS identified compounds such as α-cubebene, caryophyllene, and ipriflavone, which were computationally docked with key proteins EGFR and ER3. Discussion: The docking study exhibited good binding energy and ligand efficiency. The animals were administered different doses of extracts, and their antidiarrheal effect was appraised via castor oil-induced diarrhea, charcoal meal assay, and the in vivo antidiarrheal index was calculated. Conclusion: Further, histopathological analysis of the ileal tissue of the small intestine was conducted to support its diarrheal protection effect.
- 13 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 17, 1-17
Integrated Network Pharmacology, In Silico Analysis, and Experimental Validation to Reveal Antidiarrheal Activity of Psidium guajava L. Leaf Extract
Introduction: Psidium guajava L. (guava) is a well-known equatorial plant exploited for food and medicinal purposes. The present study is based on the antidiarrheal activity of the hydroalcoholic extract of its leaves in castor oil-induced diarrhea. Methods: The extract was analysed by GC-MS, and secondary metabolites were identified. The pharmacokinetic analysis and toxicity profiling of the identified components were performed. The network pharmacological analysis was performed to find compound-key target interaction pathways. In silico docking analysis was performed against epidermal growth factor receptor (EGFR) and prostaglandin E receptor 3 (EP3), and ligand binding efficiency was calculated. The diarrheal model was developed by administering castor oil and evaluated antidiarrheal activities using loperamide as a standard drug. Results: GC-MS identified major compounds that were screened for physicochemical properties and toxicity profiling, and network pharmacological pathways were established. GC-MS identified compounds such as α-cubebene, caryophyllene, and ipriflavone, which were computationally docked with key proteins EGFR and ER3. Discussion: The docking study exhibited good binding energy and ligand efficiency. The animals were administered different doses of extracts, and their antidiarrheal effect was appraised via castor oil-induced diarrhea, charcoal meal assay, and the in vivo antidiarrheal index was calculated. Conclusion: Further, histopathological analysis of the ileal tissue of the small intestine was conducted to support its diarrheal protection effect.
- 9 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Anti-Infective Drug Discovery
- Vol. 21, 1-32
Computational Strategies for Investigating Phytochemicals in Drug-resistant Tuberculosis
Introduction: Tuberculosis (TB) is a serious global health concern precipitated by the pathogen Mycobacterium tuberculosis. The manifestation of drug-resistant forms of tuberculosis, such as extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains, makes treatment more difficult. Methods: Innovative methods are required to find novel therapies because traditional drug development procedures are expensive and time-consuming. So, computational phytochemistry, which utilizes computer-aided techniques to create and find novel medications from natural plant molecules, provides new opportunities for the discovery of antitubercular agents. (DR-TB). This review aims to critically evaluate the potential of computational phytochemistry in accelerating the discovery of phytochemical-based therapeutics against drug-resistant tuberculosis. Relevant literature was examined, focusing on computational approaches including molecular docking, virtual screening, quantitative structure– activity relationship (QSAR) analysis, molecular dynamics (MD) simulations, artificial intelligence- assisted screening, pharmacophore modeling, and ADMET prediction for identifying promising anti-TB phytochemicals targeting key Mycobacterium tuberculosis proteins. Results: The reviewed studies revealed that several classes of phytochemicals, including flavonoids, alkaloids, terpenoids, and phenolic compounds, demonstrated strong binding affinities toward validated drug-resistant TB targets such as InhA, DprE1, KasA, PknB, and DNA gyrase. Studies employing integrated computational workflows combining molecular docking, molecular dynamics simulations, and ADMET analyses provided more reliable predictions than docking-only approaches, facilitating the identification and optimization of potential anti-TB lead compounds. Discussion: Given the prevalence of DR-TB and the shortcomings of existing treatments, this strategy tackles the urgent need for novel treatments. By fusing the enormous diversity of plant chemicals with computational capacity, this research offers a viable path for the revelation and development of unprecedented natural product-based anti-TB medications. Conclusion: Computational phytochemistry represents a promising and cost-effective strategy for prioritizing phytochemicals against MDR/XDR-TB. These encouraging in silico findings must be translated into successful treatments for drug-resistant tuberculosis, which will require more in vitro antimycobacterial screening, target-based biochemical assays, pharmacokinetic and toxicity studies, in vivo efficacy evaluation in tuberculosis models, and ultimately clinical validation. Future studies should also integrate artificial intelligence- driven drug discovery and multi-target screening approaches to improve hit identification and lead optimization for combating drug-resistant tuberculosis.
- 9 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Anti-Infective Drug Discovery
- Vol. 21, 1-32
Computational Strategies for Investigating Phytochemicals in Drug-resistant Tuberculosis
Introduction: Tuberculosis (TB) is a serious global health concern precipitated by the pathogen Mycobacterium tuberculosis. The manifestation of drug-resistant forms of tuberculosis, such as extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains, makes treatment more difficult. Methods: Innovative methods are required to find novel therapies because traditional drug development procedures are expensive and time-consuming. So, computational phytochemistry, which utilizes computer-aided techniques to create and find novel medications from natural plant molecules, provides new opportunities for the discovery of antitubercular agents. (DR-TB). This review aims to critically evaluate the potential of computational phytochemistry in accelerating the discovery of phytochemical-based therapeutics against drug-resistant tuberculosis. Relevant literature was examined, focusing on computational approaches including molecular docking, virtual screening, quantitative structure– activity relationship (QSAR) analysis, molecular dynamics (MD) simulations, artificial intelligence- assisted screening, pharmacophore modeling, and ADMET prediction for identifying promising anti-TB phytochemicals targeting key Mycobacterium tuberculosis proteins. Results: The reviewed studies revealed that several classes of phytochemicals, including flavonoids, alkaloids, terpenoids, and phenolic compounds, demonstrated strong binding affinities toward validated drug-resistant TB targets such as InhA, DprE1, KasA, PknB, and DNA gyrase. Studies employing integrated computational workflows combining molecular docking, molecular dynamics simulations, and ADMET analyses provided more reliable predictions than docking-only approaches, facilitating the identification and optimization of potential anti-TB lead compounds. Discussion: Given the prevalence of DR-TB and the shortcomings of existing treatments, this strategy tackles the urgent need for novel treatments. By fusing the enormous diversity of plant chemicals with computational capacity, this research offers a viable path for the revelation and development of unprecedented natural product-based anti-TB medications. Conclusion: Computational phytochemistry represents a promising and cost-effective strategy for prioritizing phytochemicals against MDR/XDR-TB. These encouraging in silico findings must be translated into successful treatments for drug-resistant tuberculosis, which will require more in vitro antimycobacterial screening, target-based biochemical assays, pharmacokinetic and toxicity studies, in vivo efficacy evaluation in tuberculosis models, and ultimately clinical validation. Future studies should also integrate artificial intelligence- driven drug discovery and multi-target screening approaches to improve hit identification and lead optimization for combating drug-resistant tuberculosis.
- 1 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 23 (9) , 1099-1114
Glycosylation in Cancer Medicines Delivery and Their Patents
Glycosylation plays a significant part in cancer pathophysiology, shaping tumour progression, metastasis, immune evasion, and drug resistance. Aberrant glycosylation patterns in tumours serve as impending biomarkers and therapeutic targets for enriched cancer diagnostics and treatment strategies. Developments in glycosylation-mediated drug delivery systems (DDSs) have enabled more targeted targeting of tumour cells through receptor-specific interactions, boosting drug efficacy while mitigating systemic toxicity. Glycosylated nanocarriers, antibodies, and fusion proteins have proven favourable applications in anticancer therapies, improving drug stability, cellular uptake, and immune modulation. Recent patents focus on innovative advances leveraging glycosylation to improve drug targeting, stability, and therapeutic efficacy, predominantly in addressing multidrug resistance in cancers such as non-small cell lung cancer, breast cancer, and prostate cancer. Narrative review, synthesizing published research and patents related to glycosylation-mediated drug delivery for cancer. Peer-reviewed journal articles and patents retrieved from European, Google Patents, and Lens.org databases (2020–2025) using keywords such as cancer, glycosylation, drug, medicine, oncology. Covers glycosylation biology in cancer, receptor-mediated targeting, applications in nanocarriers and antibodies, roles in metastasis, immune evasion, metabolism, ferroptosis, senescence, biomarkers, and delivery systems. Qualitative synthesis of literature findings and patent specifications, categorizing them by therapeutic approach, target, stage of development, and potential for clinical translation. Identification of trends, challenges, and future perspectives in glycosylation-based drug delivery. This review surveys the structural and functional aspects of glycosylation in cancer biology, its effects on tumour behaviour, and its emerging role in personalised medicine through glycosylation-based diagnostics and targeted therapeutics.
- 1 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 23 (9) , 1099-1114
Glycosylation in Cancer Medicines Delivery and Their Patents
Glycosylation plays a significant part in cancer pathophysiology, shaping tumour progression, metastasis, immune evasion, and drug resistance. Aberrant glycosylation patterns in tumours serve as impending biomarkers and therapeutic targets for enriched cancer diagnostics and treatment strategies. Developments in glycosylation-mediated drug delivery systems (DDSs) have enabled more targeted targeting of tumour cells through receptor-specific interactions, boosting drug efficacy while mitigating systemic toxicity. Glycosylated nanocarriers, antibodies, and fusion proteins have proven favourable applications in anticancer therapies, improving drug stability, cellular uptake, and immune modulation. Recent patents focus on innovative advances leveraging glycosylation to improve drug targeting, stability, and therapeutic efficacy, predominantly in addressing multidrug resistance in cancers such as non-small cell lung cancer, breast cancer, and prostate cancer. Narrative review, synthesizing published research and patents related to glycosylation-mediated drug delivery for cancer. Peer-reviewed journal articles and patents retrieved from European, Google Patents, and Lens.org databases (2020–2025) using keywords such as cancer, glycosylation, drug, medicine, oncology. Covers glycosylation biology in cancer, receptor-mediated targeting, applications in nanocarriers and antibodies, roles in metastasis, immune evasion, metabolism, ferroptosis, senescence, biomarkers, and delivery systems. Qualitative synthesis of literature findings and patent specifications, categorizing them by therapeutic approach, target, stage of development, and potential for clinical translation. Identification of trends, challenges, and future perspectives in glycosylation-based drug delivery. This review surveys the structural and functional aspects of glycosylation in cancer biology, its effects on tumour behaviour, and its emerging role in personalised medicine through glycosylation-based diagnostics and targeted therapeutics.
- 30 July 2026
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 26, 1-26
Multi-Target Neuroprotection by Phytochemicals: Mechanisms, Clinical Evidence, and Translational Strategies for Neurodegenerative Disorders
Introduction: Neurological disorders (NDs) represent a significant and rapidly increasing global health problem, resulting in the progressive loss of neurons and cognitive decline. Current treatments are symptomatic and have major side effects. This review provides a detailed discussion on the roles and modes of action of the phytocompounds, their mechanistic pathways, and the challenges and opportunities, along with their clinical translation. Method: Relevant literature published in peer-reviewed journals was collected from databases including PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar using keywords related to phytochemicals, neuroprotection, oxidative stress, inflammation, and neurological disorders. Studies focusing on the mechanistic and therapeutic roles of plant-derived bioactive compounds were critically analyzed. Results: The application of different phytocompounds, including polyphenols, flavonoids, alkaloids, and terpenoids, is discussed. In addition, the roles and modes of action of phytocompounds such as curcumin, resveratrol, and epigallocatechin gallate (EGCG) have been discussed in relation to oxidative stress, inflammation, and protein aggregation. Their therapeutic actions are mediated via key mechanistic pathways, such as NF-κB inhibition, Nrf2/ARE activation, anti- apoptotic effects, neurotransmitter regulation, and chelation of redox-active metals. Discussion: Emerging evidence suggests that phytochemicals may mitigate oxidative stress, neuroinflammation, and neuronal damage associated with NDs. However, variability in phytochemical composition and insufficient clinical validation remain major concerns. Phytochemicals possess multi-target neuroprotective activities and may serve as promising therapeutic candidates for NDs. Challenges and Future Directions: The existing limitations, such as poor bioavailability, lack of standardization, and regulatory barriers, prevent clinical translation. The recent advances, including nanocarrier-based delivery of plant-derived drugs, artificial intelligence-driven phytocompound modelling, and pharmacogenomics-based personalized therapy, have been discussed. Conclusion: Phytochemicals hold significant promise for neurotherapeutics. Nevertheless, their clinical application in several NDs requires advances in targeted drug delivery systems, precision medicine, standardized formulations, and robust mechanistic and clinical studies.
- 30 July 2026
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 26, 1-26
Multi-Target Neuroprotection by Phytochemicals: Mechanisms, Clinical Evidence, and Translational Strategies for Neurodegenerative Disorders
Introduction: Neurological disorders (NDs) represent a significant and rapidly increasing global health problem, resulting in the progressive loss of neurons and cognitive decline. Current treatments are symptomatic and have major side effects. This review provides a detailed discussion on the roles and modes of action of the phytocompounds, their mechanistic pathways, and the challenges and opportunities, along with their clinical translation. Method: Relevant literature published in peer-reviewed journals was collected from databases including PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar using keywords related to phytochemicals, neuroprotection, oxidative stress, inflammation, and neurological disorders. Studies focusing on the mechanistic and therapeutic roles of plant-derived bioactive compounds were critically analyzed. Results: The application of different phytocompounds, including polyphenols, flavonoids, alkaloids, and terpenoids, is discussed. In addition, the roles and modes of action of phytocompounds such as curcumin, resveratrol, and epigallocatechin gallate (EGCG) have been discussed in relation to oxidative stress, inflammation, and protein aggregation. Their therapeutic actions are mediated via key mechanistic pathways, such as NF-κB inhibition, Nrf2/ARE activation, anti- apoptotic effects, neurotransmitter regulation, and chelation of redox-active metals. Discussion: Emerging evidence suggests that phytochemicals may mitigate oxidative stress, neuroinflammation, and neuronal damage associated with NDs. However, variability in phytochemical composition and insufficient clinical validation remain major concerns. Phytochemicals possess multi-target neuroprotective activities and may serve as promising therapeutic candidates for NDs. Challenges and Future Directions: The existing limitations, such as poor bioavailability, lack of standardization, and regulatory barriers, prevent clinical translation. The recent advances, including nanocarrier-based delivery of plant-derived drugs, artificial intelligence-driven phytocompound modelling, and pharmacogenomics-based personalized therapy, have been discussed. Conclusion: Phytochemicals hold significant promise for neurotherapeutics. Nevertheless, their clinical application in several NDs requires advances in targeted drug delivery systems, precision medicine, standardized formulations, and robust mechanistic and clinical studies.
- 18 June 2026
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 20, 1-12
A Comprehensive Review on Ethnomedicinal Properties of Curcuma caesia Roxb.
Curcuma caesia Roxb. is commonly known as black turmeric. It is a valuable medicinal plant of the Zingiberaceae family in traditional systems of medicine. Its bioactive chemical constituents have been associated with a wide range of pharmacological properties, including antibacterial, antifungal, antioxidant, hepatoprotective, anticonvulsant, analgesic, anti-inflammatory, muscle relaxant, anti-diabetic, and antiurolithiatic activities, etc. The major chemical constituents present in Curcuma caesia are camphor, 1,8-cineole, ar-turmerone, ar-curcumene, and borneol, etc. In addition, the plant also contains anthocyanins, which impart its distinctive bluish-black color. But there are not enough comprehensive pharmacological investigations to support the efficacy and safety of several ethnomedical properties. There is also inadequate knowledge of the molecular mechanisms underlying its therapeutic benefits, with limited data on toxicity, safety profile, and long-term effects. There is a lack of randomized controlled trials (RCTs) with effect sizes and confidence intervals (CIs). So, this study focuses on current research findings on the phytochemistry and therapeutic uses of Curcuma caesia. This review also highlights the opportunities and challenges in new drug development using Curcuma caesia in natural product research.
- 18 June 2026
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 20, 1-12
A Comprehensive Review on Ethnomedicinal Properties of Curcuma caesia Roxb.
Curcuma caesia Roxb. is commonly known as black turmeric. It is a valuable medicinal plant of the Zingiberaceae family in traditional systems of medicine. Its bioactive chemical constituents have been associated with a wide range of pharmacological properties, including antibacterial, antifungal, antioxidant, hepatoprotective, anticonvulsant, analgesic, anti-inflammatory, muscle relaxant, anti-diabetic, and antiurolithiatic activities, etc. The major chemical constituents present in Curcuma caesia are camphor, 1,8-cineole, ar-turmerone, ar-curcumene, and borneol, etc. In addition, the plant also contains anthocyanins, which impart its distinctive bluish-black color. But there are not enough comprehensive pharmacological investigations to support the efficacy and safety of several ethnomedical properties. There is also inadequate knowledge of the molecular mechanisms underlying its therapeutic benefits, with limited data on toxicity, safety profile, and long-term effects. There is a lack of randomized controlled trials (RCTs) with effect sizes and confidence intervals (CIs). So, this study focuses on current research findings on the phytochemistry and therapeutic uses of Curcuma caesia. This review also highlights the opportunities and challenges in new drug development using Curcuma caesia in natural product research.
- 6 May 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 23, 1-13
Assessment of the Hepatoprotective and Antioxidant Properties of Hydroalcoholic Extract of Paederia foetida
Background: Nowadays, health issues are common due to lifestyle modifications and a lack of body immunity. This study primarily focuses on the putative action of Paerida foetida by using a hydroalcoholic extract for antioxidant and liver disorders. Methods: Antioxidant properties were evaluated by using DPPH radical scavenging assays. An LC-MS study was carried out for the characterization of compounds. Total Phenolic and flavonoid content were estimated using standard methods. Hepatotoxicity was induced in Swiss mice (25-35 g) by a CCl₄ and corn oil (1:1 v/v) mixture at 2 ml/kg. Then they are treated with Paerida foetida (500 gm/kg and 250 mg/kg) hydroalcoholic extract orally for 21 days. Results: Paerida foetida (500mg/kg) extract exhibits a significant preventive action against liver disorders, as evidenced by a significant reduction (p < 0.001) in high serum levels of AST, ALT, ALP, total bilirubin, and total protein content. The phenolic and flavonoid contents in P. foetida are responsible for antioxidant and hepatoprotective activities. The underlying molecule of Paerida foetida is responsible for an effective ameliorator of liver disease changes at the hepatic level (p < 0.001) of MDA, GSH, and SOD. Discussion: Furthermore, hepatological studies of CCl4-induced necrosis cells have shown an effective cell-healing potency by sylimarin and P. foetida (500mg/kg) extract. LC-MS data revealed the presence of Pterostilbene, flavone, Neoagarobiose, Lathosterol, Sitosterol, and many other acidic esters. Conclusion: Finally, it is concluded that the hydroalcoholic extract of Paerida foetida is a valuable therapeutic herb to prevent liver deterioration and also an antioxidant agent due to the presence of the above-mentioned constituents as major compounds, identified by LC-MS in the plant extract.
- 6 May 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 23, 1-13
Assessment of the Hepatoprotective and Antioxidant Properties of Hydroalcoholic Extract of Paederia foetida
Background: Nowadays, health issues are common due to lifestyle modifications and a lack of body immunity. This study primarily focuses on the putative action of Paerida foetida by using a hydroalcoholic extract for antioxidant and liver disorders. Methods: Antioxidant properties were evaluated by using DPPH radical scavenging assays. An LC-MS study was carried out for the characterization of compounds. Total Phenolic and flavonoid content were estimated using standard methods. Hepatotoxicity was induced in Swiss mice (25-35 g) by a CCl₄ and corn oil (1:1 v/v) mixture at 2 ml/kg. Then they are treated with Paerida foetida (500 gm/kg and 250 mg/kg) hydroalcoholic extract orally for 21 days. Results: Paerida foetida (500mg/kg) extract exhibits a significant preventive action against liver disorders, as evidenced by a significant reduction (p < 0.001) in high serum levels of AST, ALT, ALP, total bilirubin, and total protein content. The phenolic and flavonoid contents in P. foetida are responsible for antioxidant and hepatoprotective activities. The underlying molecule of Paerida foetida is responsible for an effective ameliorator of liver disease changes at the hepatic level (p < 0.001) of MDA, GSH, and SOD. Discussion: Furthermore, hepatological studies of CCl4-induced necrosis cells have shown an effective cell-healing potency by sylimarin and P. foetida (500mg/kg) extract. LC-MS data revealed the presence of Pterostilbene, flavone, Neoagarobiose, Lathosterol, Sitosterol, and many other acidic esters. Conclusion: Finally, it is concluded that the hydroalcoholic extract of Paerida foetida is a valuable therapeutic herb to prevent liver deterioration and also an antioxidant agent due to the presence of the above-mentioned constituents as major compounds, identified by LC-MS in the plant extract.
- 5 May 2026
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 20 (3) , 1-16
Strategies and Challenges of Herbal Medicines in Cancer Therapy
Introduction: Cancer is a continued health burden across the world, and the existing cancer treatments, including chemotherapy, radiotherapy, and surgery, have been associated with several toxic side effects. The increasing interest in the use of herbal medicine and phytochemicals from medicinal plants is attributed to their potential as complementary treatments that can enhance cancer therapy, reduce toxicities, and improve existing treatments. Evidence for their use has continued to increase. Methods: The review was conducted by thoroughly evaluating the published literature on the therapeutic efficacy of herbal medicines and plant-derived phytochemicals in treating cancer. A number of clinical and preclinical studies were also assessed to understand the mechanisms and safety profiles associated with their therapeutic efficacy in combating cancer. Results: The results indicate the potential of different herbal medicines and phytochemicals with significant anticancer properties, which can act by inducing apoptosis, inhibiting tumor cell proliferation, interfering with various cellular processes, or boosting the immune system. Discussion: Recent developments in scientific knowledge and the applications of herbal drugs make their potential use in cancer treatment significant. Even though the initial outcomes are quite promising, the lack of appropriate frameworks and quality control during the implementation of herbal drugs is challenging. Conclusion: The review forms the basis for the safe, effective, and scientifically approved use of herbal medicines in the treatment of cancer. It makes an important contribution to the rational use of herbal medicines in the treatment of cancer by highlighting the drawbacks of existing conditions and opportunities to address them.
- 5 May 2026
- Published by Bentham Science Publishers Ltd. in Current Chemical Biology
- Vol. 20 (3) , 1-16
Strategies and Challenges of Herbal Medicines in Cancer Therapy
Introduction: Cancer is a continued health burden across the world, and the existing cancer treatments, including chemotherapy, radiotherapy, and surgery, have been associated with several toxic side effects. The increasing interest in the use of herbal medicine and phytochemicals from medicinal plants is attributed to their potential as complementary treatments that can enhance cancer therapy, reduce toxicities, and improve existing treatments. Evidence for their use has continued to increase. Methods: The review was conducted by thoroughly evaluating the published literature on the therapeutic efficacy of herbal medicines and plant-derived phytochemicals in treating cancer. A number of clinical and preclinical studies were also assessed to understand the mechanisms and safety profiles associated with their therapeutic efficacy in combating cancer. Results: The results indicate the potential of different herbal medicines and phytochemicals with significant anticancer properties, which can act by inducing apoptosis, inhibiting tumor cell proliferation, interfering with various cellular processes, or boosting the immune system. Discussion: Recent developments in scientific knowledge and the applications of herbal drugs make their potential use in cancer treatment significant. Even though the initial outcomes are quite promising, the lack of appropriate frameworks and quality control during the implementation of herbal drugs is challenging. Conclusion: The review forms the basis for the safe, effective, and scientifically approved use of herbal medicines in the treatment of cancer. It makes an important contribution to the rational use of herbal medicines in the treatment of cancer by highlighting the drawbacks of existing conditions and opportunities to address them.
- Open Access
- 25 April 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 961-975
Overview of Nutritional Value and Pharmacological Properties of Millets
Background: Millets are small grains grown in arid climates and are rich in minerals, vitamins, and phytochemicals, making them highly nutritious. Their nutritional profile, which includes vitamins, dietary fibre, protein, and antioxidants, supports health and helps prevent disease. Aim: Millets are beneficial for managing lifestyle diseases because of their therapeutic properties, which include anti-diabetic, anti-inflammatory, antioxidant, and anti-Alzheimer’s agent properties. Methods: Additionally, their low glycemic index, gluten-free status, and ability to tolerate a variety of climates make them ideal for a range of nutritional needs and environmental sustainability. Results: The polyphenolic content of millets, namely finger millet, highlights their pharmacological potential by exhibiting antibacterial, antioxidant, and anti-diabetic properties. Conclusion: More research and studies into the use of millets in the food and pharmaceutical industries are necessary to fully realise their potential as nutrient-rich crops with significant health benefits. Major Findings:Millets, known for their high nutritional value of proteins, dietary fibres, vitamins, and minerals, are also valuable substances for improving human health and well-being. This study also reports the effects of millets on intestinal health and their possible future contributions to sustainability and global food security
- 25 April 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 961-975
Open AccessOverview of Nutritional Value and Pharmacological Properties of Millets
Background: Millets are small grains grown in arid climates and are rich in minerals, vitamins, and phytochemicals, making them highly nutritious. Their nutritional profile, which includes vitamins, dietary fibre, protein, and antioxidants, supports health and helps prevent disease. Aim: Millets are beneficial for managing lifestyle diseases because of their therapeutic properties, which include anti-diabetic, anti-inflammatory, antioxidant, and anti-Alzheimer’s agent properties. Methods: Additionally, their low glycemic index, gluten-free status, and ability to tolerate a variety of climates make them ideal for a range of nutritional needs and environmental sustainability. Results: The polyphenolic content of millets, namely finger millet, highlights their pharmacological potential by exhibiting antibacterial, antioxidant, and anti-diabetic properties. Conclusion: More research and studies into the use of millets in the food and pharmaceutical industries are necessary to fully realise their potential as nutrient-rich crops with significant health benefits. Major Findings:Millets, known for their high nutritional value of proteins, dietary fibres, vitamins, and minerals, are also valuable substances for improving human health and well-being. This study also reports the effects of millets on intestinal health and their possible future contributions to sustainability and global food security
- 12 March 2026
- Published by Bentham Science Publishers Ltd. in Current Nanomaterials
- Vol. 11, 1-10
Role of Nanotechnology for Targeted Therapy in Cancer
Nanotechnology plays a vital role in the development of targeted cancer therapies, offering the potential for more effective, accurate, and minimally invasive options for treatment. In order to improve drug accumulation within cancer cells and reduce exposure to healthy tissues, nanoparticles can be designed to deliver anticancer medications directly to the site of action. This targeted drug delivery increases the therapeutic efficacy and reduces systemic side effects. Compared to traditional therapies, nanocarriers are more effective at reaching tumor microenvironments and overcoming biological barriers due to their small size (between 1 and 100 nanometers). Nanoparticles can be loaded with a variety of agents, including chemotherapeutic agents, imaging agents, and photosensitizers, which allow for the combination of drug therapies and real-time therapy efficacy assessment. In addition to delivering drugs intracellularly, nanocarriers can also avoid drug efflux processes and can help some malignancies overcome resistance. This technology ensures localized drug therapy activation by enabling the design of nanocarriers that deliver drugs in response to specific stimuli inside the tumor microenvironment, such as temperature, enzymes, or acidic pH. With the help of nanotechnology, it is possible to develop theranostics that integrate both therapy and diagnostic imaging which enable real-time evaluation of therapeutic results and personalized treatment plans. Therefore, nanotechnology enhances the efficacy, safety, and customization of cancer treatment by enabling focused therapy, minimizing side effects, and incorporating diagnostic capabilities. These nanoplatforms are being optimized for clinical translation and better patient outcomes through ongoing research.
- 12 March 2026
- Published by Bentham Science Publishers Ltd. in Current Nanomaterials
- Vol. 11, 1-10
Role of Nanotechnology for Targeted Therapy in Cancer
Nanotechnology plays a vital role in the development of targeted cancer therapies, offering the potential for more effective, accurate, and minimally invasive options for treatment. In order to improve drug accumulation within cancer cells and reduce exposure to healthy tissues, nanoparticles can be designed to deliver anticancer medications directly to the site of action. This targeted drug delivery increases the therapeutic efficacy and reduces systemic side effects. Compared to traditional therapies, nanocarriers are more effective at reaching tumor microenvironments and overcoming biological barriers due to their small size (between 1 and 100 nanometers). Nanoparticles can be loaded with a variety of agents, including chemotherapeutic agents, imaging agents, and photosensitizers, which allow for the combination of drug therapies and real-time therapy efficacy assessment. In addition to delivering drugs intracellularly, nanocarriers can also avoid drug efflux processes and can help some malignancies overcome resistance. This technology ensures localized drug therapy activation by enabling the design of nanocarriers that deliver drugs in response to specific stimuli inside the tumor microenvironment, such as temperature, enzymes, or acidic pH. With the help of nanotechnology, it is possible to develop theranostics that integrate both therapy and diagnostic imaging which enable real-time evaluation of therapeutic results and personalized treatment plans. Therefore, nanotechnology enhances the efficacy, safety, and customization of cancer treatment by enabling focused therapy, minimizing side effects, and incorporating diagnostic capabilities. These nanoplatforms are being optimized for clinical translation and better patient outcomes through ongoing research.